



WORKPLAN

Angus PMG				Agenda Item:
Date of Meeting:	270421	Version No.	2	3

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
Out of Hours	Develop strong links and engagement with Out of Hours service to monitor financial impact. David Morrison, OOH's pharmacist to be invited to become a member of Angus PMG.	Michelle Logan Rena	230620	230620	Complete, David Morrison attended meeting 230620 and will now provide an update at each meeting.
Practice Specific Reports	Each practice in Angus will receive a tailored practice report.	Dr Scott Jamieson	180820		Complete
	Practice led single drug reviews.	Pharmacy/ Ray Pert	Ongoing		Some progress was made with these during 2020/21, but less than previous years due to impact of COVID-19 on priorities. Further identification will take place over 2021/22.

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
	LTC/polypharmacy reviews.	Cluster Leads Dr Nico Grunenberg Deirdre Cameron	3103 21		The remobilisation plans for Tayside for long term conditions support GPs with prioritisation of polypharmacy and long term condition reviews. The Angus GP QI lead is supporting Angus practices with quality improvement in this area. Future proposals include GP clusters to each carry out one quality improvement activity in relation to prescribing annually
	National Therapeutic Indicators.	Cluster Leads	3103 21		The national therapeutic indicators are increasingly reported on and their use promoted throughout various Angus HSCP forums
Impact of non-medicines	Non-pharmacological pain pathway to be launched regionally. Local promotion and support of its use in therapy.	Dr Alison Clement	Ongoing		This has been launched and its use promoted through sharing in the primary care Covid-19 newsletter, addition of links within the NHST formulary and by encouraging cluster leads to promote.

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
	Care homes – improve governance with regard to catheter use and subsequent e-coli diagnosis and treatment. This will require collaborative working with both DNs and care home staff.	Michelle Logan Rena/Karen Fletcher	180820		Karen Fletcher to be invited to join the group as a contributing member to help lead this piece of work. Current indications are a reduction in community acquired e.coli bacteraemia recently in Angus. Standards are being developed to support frail elderly care in Angus with quality improvement planned. A proposal for nursing in care home standards will be taken to Angus Clinical Partnership Group in June 2021.
Vigilance with regard to top 70 GIC medicines	Dr Jamieson will report quarterly on significant movement on spend within the top 70 GIC list.	Dr Scott Jamieson	180820		This data continues to be reviewed with some improvements identified although Covid-19 has diverted resource for prescribing saving opportunities. Latest data from Oct-Dec 2020 identifies that Chronic pain, mental health and diabetes prescribing feature prominently as areas of increased cost which may be early indications of the impact of COVID.

Objective/ Responsibility	Action	Lead	Deadline/ Meeting	Actual Completion	Update/Status
Continence care	Promotion of continence care and OAB pathway. Educational sessions planned starting in Monifieth promoting alternatives to medicines and catheters. Arbroath TOC, catheter free trials.	Lisa Henry	310321 Update 180820	October 2020	Complete
HAI standards on infection prevention and control (delivery area 1)	Antimicrobial prescribing and resistance tracking	All/Dr Scott Jamieson	Ongoing		Clusters have the opportunity to review their prescribing data on antibiotic use. Angus continues to perform well in national indicators.
Serial Prescribing	Practices within each cluster to move toward a figure of 40% of suitable patients on to serial prescriptions by March 2022.	All	Quarterly		
GP Prescribing risk BAF	Quarterly review of the GP prescribing risk and BAF noting controls in place and provision of additional assurance requirements.	All	Quarterly		This risk is now monitored regularly with the Angus prescribing management group. (Current risk score 9, formerly 25)